Description
Developer of specialty pharmaceutical products intended for the treatment of common skin conditions. The company's healthcare process develops oral and cream-based medicinal products for the treatment of conditions like skin pigmentation, eczema, atopic dermatitis, lightening and psoriasis, enabling the medical community and patients to meet and resolve unmet clinical needs.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Later Stage VC | 01-May-2021 | $1.96M | 00.000 | Completed | Generating Revenue | |
6. Later Stage VC | 01-Mar-2020 | 00000 | 00.000 | 00.000 | Completed | Generating Revenue |
5. Angel (individual) | 05-Sep-2017 | 00000 | 00.000 | 00.000 | Completed | Startup |
4. Grant | 01-May-2017 | 00000 | 00000 | Completed | Generating Revenue | |
3. Angel (individual) | 15-Aug-2016 | 00000 | 00000 | 00.000 | Completed | Startup |
2. Angel (individual) | 14-Jun-2014 | $336K | $336K | 00.000 | Completed | Startup |
1. Grant | $36.2K | Completed | Startup |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
Ordinary | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
Preferred Ordinary | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
Preferred Ordinary | 2,333,333 | $0.012974 | $0.19 | $0.19 | 1x | $0.19 | 12.06% | |
Ordinary | 2,353,329 | $0.000013 | $0.19 | $0.19 | 1x | $0.19 | 12.17% |
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
ES-2875275-T3 | Exothermic topical devices for the delivery of drugs and cosmetics to the skin | Active | 30-Nov-2015 | 0000000000 | |
GB-2544813-A | Devices and methods for delivering pharmaceuticals and cosmetics to the skin | Granted | 30-Nov-2015 | 0000000000 | 0 |
EP-3413867-A1 | Exothermic topical devices for delivering pharmaceuticals and cosmetics to the skin | Granted | 30-Nov-2015 | 0000000000 | |
GB-201521111-D0 | Devices and methods for delivering pharmaceuticals and cosmetics to the skin | Granted | 30-Nov-2015 | 0000000000 | |
US-20180353438-A1 | Exothermic topical devices for delivering pharmaceuticals and cosmetics to the skin | Abandoned | 30-Nov-2015 | A61K9/7092 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Peter Luebcke Ph.D | Chief Executive Officer | ||
Neil Gibbs Ph.D | Co-Founder, Chief Scientific Officer & Board Member | ||
Alan Williams | Finance Director |
Name | Representing | Role | Since |
---|---|---|---|
Neil Gibbs Ph.D | Curapel | Co-Founder, Chief Scientific Officer & Board Member | 000 0000 |
Terry Sadler | Self | Chairman | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Development Bank of Wales | Venture Capital | Minority | 000 0000 | 000000 0 | |
Meltwind | Venture Capital | Minority | 000 0000 | 000000 0 | |
Innovate UK | Government | 000 0000 | 000000 0 | ||
Lancaster Capital | Angel Group | Minority | 000 0000 | 000000 0 | |
Biotechnology and Biological Science Research Council | Limited Partner | 000 0000 | 000000 0 |